Belinostat
Belinostat is a histone deacetylase (HDAC) inhibitor that exhibits antiviral and anticancer chemotherapeutic activities. Belinostat is approved for use in humans in the treatment of T cell lymphoma and is currently in clinical trials as a potential treatment for other leukemias and lymphomas. In pancreatic cancer cells, belinostat induces apoptosis in an AMPK-dependent manner. In other cellular models, this compound decreases HIV release from macrophages by degrading intracellular HIV.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/1884314
| Cas No. |
414864-00-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C15H14N2O4S |
| Formula Wt. |
318.35 |
| Synonym |
PXD101 |
| Appearance |
Pale yellow powder |
Campbell GR, Bruckman RS, Chu YL, et al. Autophagy Induction by Histone Deacetylase Inhibitors Inhibits HIV Type 1. J Biol Chem. 2015 Feb 20;290(8):5028-40. PMID: 25540204.
Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma. Br J Haematol. 2014 Nov 17. [Epub ahead of print].
PMID: 25404094.
Kirschbaum MH, Foon KA, Frankel P, et al. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study. Leuk Lymphoma. 2014 Oct;55(10):2301-4. PMID: 24369094.
Wang B, Wang XB, Chen LY, et al. Belinostat-induced apoptosis and growth inhibition in pancreatic cancer cells involve activation of TAK1-AMPK signaling axis. Biochem Biophys Res Commun. 2013 Jul 19;437(1):1-6. PMID: 23743198.
